← All trials
NCT03700411
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 7, 2019
- Primary completion
- Jan 31, 2021
- Completion date
- Jan 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- The Institute of Molecular and Translational Medicine, Czech RepublicLead sponsor
- Tomas Bata Hospital ZlinCollaborator
- Charles UniversityCollaborator
- University of OstravaCollaborator
- The Institute of Molecular and Translational Medicine, Czech RepublicReponsible party - principal investigator
- Palacky UniversityOverall official - principal investigator
- Hospital Novy JicinCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.